Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...

A Florida man with a terminal illness faces losing vital hospice care due to an administrative error, leaving his family in ...

Theravance Biopharma shares tumble after Phase 3 trial fails, company halts drug program and explores sale options ahead of ...

Another phase III failure of Theravance Biopharma Inc.’s norepinephrine reuptake inhibitor ampreloxetine to treat symptomatic neurogenic orthostatic hypotension, this time in patients with the rare ...

Theravance Biopharma (TBPH) stock is in focus as the firm halts the clinical program for rare disease therapy ampreloxetine ...

Theravance Biopharma said on Tuesday its board is reviewing strategic alternatives, including a ​possible sale, after ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

Add Yahoo as a preferred source to see more of our stories on Google. Multiple systems will bring the West beneficial rain and mountain snow. The first round moves in Wednesday into Thursday, but that ...

The biopharmaceutical company said Tuesday that its restructuring includes the complete wind down of its research and development organization, as well as a roughly 50% decrease in general and ...

Theravance Biopharma is set to lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that ...

RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS ...